Lysophospholipid metabolism, clinical characteristics, and artificial intelligence-based quantitative assessments of chest CT in patients with stable COPD and healthy smokers
Abstract The specific role of lysophospholipids (LysoPLs) in the pathogenesis of chronic obstructive pulmonary disease (COPD) is not yet fully understood. We determined serum LysoPLs in 20 patients with stable COPD and 20 healthy smokers using liquid chromatography–mass spectrometry (LC–MS) and matc...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-11960-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849766309737267200 |
|---|---|
| author | Qiqiang Zhou Lvxinhe Xing Mi Ma Bianba Qiongda Deyuan Li Ping Wang Yahong Chen Ying Liang Meilang ChuTso Yongchang Sun |
| author_facet | Qiqiang Zhou Lvxinhe Xing Mi Ma Bianba Qiongda Deyuan Li Ping Wang Yahong Chen Ying Liang Meilang ChuTso Yongchang Sun |
| author_sort | Qiqiang Zhou |
| collection | DOAJ |
| description | Abstract The specific role of lysophospholipids (LysoPLs) in the pathogenesis of chronic obstructive pulmonary disease (COPD) is not yet fully understood. We determined serum LysoPLs in 20 patients with stable COPD and 20 healthy smokers using liquid chromatography–mass spectrometry (LC–MS) and matching with the lipidIMMS library, and integrated these data with spirometry, systemic inflammation markers, and quantitative chest CT generated by an automated 3D-U-Net artificial intelligence algorithm model. Our findings identified three differential LysoPLs, lysophosphatidylcholine (LPC) (18:0), LPC (18:1), and LPC (18:2), which were significantly lower in the COPD group than in healthy smokers. Significant negative correlations were observed between these LPCs and the inflammatory markers C-reactive protein and Interleukin-6. LPC (18:0) and (18:2) correlated with higher post-bronchodilator FEV1, and the latter also correlated with FEV1% predicted, forced vital capacity (FVC), and FEV1/FVC ratio. Additionally, these three LPCs were negatively correlated with the volume and percentage of low attenuation areas (LAA), high-attenuation areas (HAA), honeycombing, reticular patterns, ground-glass opacities (GGO), and consolidation on CT imaging. In the patients with COPD, the three LPCs were most significantly associated with HAA and GGO. In conclusion, patients with stable COPD exhibited a unique LysoPL metabolism profile, with LPC (18:0), LPC (18:1), and LPC (18:2) being the most significantly altered lipid molecules. The reduction in these three LPCs was associated with impaired pulmonary function and were also linked to a greater extent of emphysema and interstitial lung abnormalities. |
| format | Article |
| id | doaj-art-0cf409e6bd334faa9a71fbee19870e6b |
| institution | DOAJ |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-0cf409e6bd334faa9a71fbee19870e6b2025-08-20T03:04:38ZengNature PortfolioScientific Reports2045-23222025-07-0115111510.1038/s41598-025-11960-5Lysophospholipid metabolism, clinical characteristics, and artificial intelligence-based quantitative assessments of chest CT in patients with stable COPD and healthy smokersQiqiang Zhou0Lvxinhe Xing1Mi Ma2Bianba Qiongda3Deyuan Li4Ping Wang5Yahong Chen6Ying Liang7Meilang ChuTso8Yongchang Sun9Department of Respiratory and Critical Care Medicine, Peking University Third HospitalDepartment of Respiratory and Critical Care Medicine, Peking University Third HospitalDepartment of Respiratory and Critical Care Medicine, Tibet Autonomous Region People’s HospitalDepartment of Respiratory and Critical Care Medicine, Tibet Autonomous Region People’s HospitalYizhiyuan Health Technology (Hangzhou) Co., Ltd.,Yizhiyuan Health Technology (Hangzhou) Co., Ltd.,Department of Respiratory and Critical Care Medicine, Peking University Third HospitalDepartment of Respiratory and Critical Care Medicine, Peking University Third HospitalDepartment of Respiratory and Critical Care Medicine, Tibet Autonomous Region People’s HospitalDepartment of Respiratory and Critical Care Medicine, Peking University Third HospitalAbstract The specific role of lysophospholipids (LysoPLs) in the pathogenesis of chronic obstructive pulmonary disease (COPD) is not yet fully understood. We determined serum LysoPLs in 20 patients with stable COPD and 20 healthy smokers using liquid chromatography–mass spectrometry (LC–MS) and matching with the lipidIMMS library, and integrated these data with spirometry, systemic inflammation markers, and quantitative chest CT generated by an automated 3D-U-Net artificial intelligence algorithm model. Our findings identified three differential LysoPLs, lysophosphatidylcholine (LPC) (18:0), LPC (18:1), and LPC (18:2), which were significantly lower in the COPD group than in healthy smokers. Significant negative correlations were observed between these LPCs and the inflammatory markers C-reactive protein and Interleukin-6. LPC (18:0) and (18:2) correlated with higher post-bronchodilator FEV1, and the latter also correlated with FEV1% predicted, forced vital capacity (FVC), and FEV1/FVC ratio. Additionally, these three LPCs were negatively correlated with the volume and percentage of low attenuation areas (LAA), high-attenuation areas (HAA), honeycombing, reticular patterns, ground-glass opacities (GGO), and consolidation on CT imaging. In the patients with COPD, the three LPCs were most significantly associated with HAA and GGO. In conclusion, patients with stable COPD exhibited a unique LysoPL metabolism profile, with LPC (18:0), LPC (18:1), and LPC (18:2) being the most significantly altered lipid molecules. The reduction in these three LPCs was associated with impaired pulmonary function and were also linked to a greater extent of emphysema and interstitial lung abnormalities.https://doi.org/10.1038/s41598-025-11960-5Chronic obstructive pulmonary diseaseLysophospholipidsChest CTLipidomicsSystemic inflammation |
| spellingShingle | Qiqiang Zhou Lvxinhe Xing Mi Ma Bianba Qiongda Deyuan Li Ping Wang Yahong Chen Ying Liang Meilang ChuTso Yongchang Sun Lysophospholipid metabolism, clinical characteristics, and artificial intelligence-based quantitative assessments of chest CT in patients with stable COPD and healthy smokers Scientific Reports Chronic obstructive pulmonary disease Lysophospholipids Chest CT Lipidomics Systemic inflammation |
| title | Lysophospholipid metabolism, clinical characteristics, and artificial intelligence-based quantitative assessments of chest CT in patients with stable COPD and healthy smokers |
| title_full | Lysophospholipid metabolism, clinical characteristics, and artificial intelligence-based quantitative assessments of chest CT in patients with stable COPD and healthy smokers |
| title_fullStr | Lysophospholipid metabolism, clinical characteristics, and artificial intelligence-based quantitative assessments of chest CT in patients with stable COPD and healthy smokers |
| title_full_unstemmed | Lysophospholipid metabolism, clinical characteristics, and artificial intelligence-based quantitative assessments of chest CT in patients with stable COPD and healthy smokers |
| title_short | Lysophospholipid metabolism, clinical characteristics, and artificial intelligence-based quantitative assessments of chest CT in patients with stable COPD and healthy smokers |
| title_sort | lysophospholipid metabolism clinical characteristics and artificial intelligence based quantitative assessments of chest ct in patients with stable copd and healthy smokers |
| topic | Chronic obstructive pulmonary disease Lysophospholipids Chest CT Lipidomics Systemic inflammation |
| url | https://doi.org/10.1038/s41598-025-11960-5 |
| work_keys_str_mv | AT qiqiangzhou lysophospholipidmetabolismclinicalcharacteristicsandartificialintelligencebasedquantitativeassessmentsofchestctinpatientswithstablecopdandhealthysmokers AT lvxinhexing lysophospholipidmetabolismclinicalcharacteristicsandartificialintelligencebasedquantitativeassessmentsofchestctinpatientswithstablecopdandhealthysmokers AT mima lysophospholipidmetabolismclinicalcharacteristicsandartificialintelligencebasedquantitativeassessmentsofchestctinpatientswithstablecopdandhealthysmokers AT bianbaqiongda lysophospholipidmetabolismclinicalcharacteristicsandartificialintelligencebasedquantitativeassessmentsofchestctinpatientswithstablecopdandhealthysmokers AT deyuanli lysophospholipidmetabolismclinicalcharacteristicsandartificialintelligencebasedquantitativeassessmentsofchestctinpatientswithstablecopdandhealthysmokers AT pingwang lysophospholipidmetabolismclinicalcharacteristicsandartificialintelligencebasedquantitativeassessmentsofchestctinpatientswithstablecopdandhealthysmokers AT yahongchen lysophospholipidmetabolismclinicalcharacteristicsandartificialintelligencebasedquantitativeassessmentsofchestctinpatientswithstablecopdandhealthysmokers AT yingliang lysophospholipidmetabolismclinicalcharacteristicsandartificialintelligencebasedquantitativeassessmentsofchestctinpatientswithstablecopdandhealthysmokers AT meilangchutso lysophospholipidmetabolismclinicalcharacteristicsandartificialintelligencebasedquantitativeassessmentsofchestctinpatientswithstablecopdandhealthysmokers AT yongchangsun lysophospholipidmetabolismclinicalcharacteristicsandartificialintelligencebasedquantitativeassessmentsofchestctinpatientswithstablecopdandhealthysmokers |